JP2022500034A - 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法 - Google Patents

抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法 Download PDF

Info

Publication number
JP2022500034A
JP2022500034A JP2021513327A JP2021513327A JP2022500034A JP 2022500034 A JP2022500034 A JP 2022500034A JP 2021513327 A JP2021513327 A JP 2021513327A JP 2021513327 A JP2021513327 A JP 2021513327A JP 2022500034 A JP2022500034 A JP 2022500034A
Authority
JP
Japan
Prior art keywords
peptides
cells
antigen
library
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021513327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500034A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ アンドリュー ラケストロウ,
ショーン ケアリー,
Original Assignee
トルク セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トルク セラピューティクス, インコーポレイテッド filed Critical トルク セラピューティクス, インコーポレイテッド
Publication of JP2022500034A publication Critical patent/JP2022500034A/ja
Publication of JP2022500034A5 publication Critical patent/JP2022500034A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021513327A 2018-09-10 2019-09-10 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法 Withdrawn JP2022500034A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862729220P 2018-09-10 2018-09-10
US62/729,220 2018-09-10
US201962884527P 2019-08-08 2019-08-08
US62/884,527 2019-08-08
PCT/US2019/050492 WO2020055931A1 (en) 2018-09-10 2019-09-10 Antigen-specific t lymphocytes and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2022500034A true JP2022500034A (ja) 2022-01-04
JP2022500034A5 JP2022500034A5 (cg-RX-API-DMAC7.html) 2022-09-21

Family

ID=69778456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513327A Withdrawn JP2022500034A (ja) 2018-09-10 2019-09-10 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法

Country Status (7)

Country Link
US (1) US20220033766A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849569A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022500034A (cg-RX-API-DMAC7.html)
AU (1) AU2019339332A1 (cg-RX-API-DMAC7.html)
CA (1) CA3112471A1 (cg-RX-API-DMAC7.html)
IL (1) IL281339A (cg-RX-API-DMAC7.html)
WO (1) WO2020055931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
US20260234258A1 (en) 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038833T2 (hu) * 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US20140081012A1 (en) 2011-02-15 2014-03-20 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
MX2017000630A (es) * 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles

Also Published As

Publication number Publication date
US20220033766A1 (en) 2022-02-03
CA3112471A1 (en) 2020-03-19
EP3849569A4 (en) 2022-06-08
WO2020055931A1 (en) 2020-03-19
EP3849569A1 (en) 2021-07-21
IL281339A (en) 2021-04-29
AU2019339332A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
JP7855622B2 (ja) T細胞製造組成物および方法
JP7181917B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
JP7054418B2 (ja) T細胞を製造する組成物及び方法
KR102809909B1 (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
JP6207783B2 (ja) 抗原特異的t細胞の増殖のための方法
EP1814580B1 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
US20220033766A1 (en) Antigen-specific t lymphocytes and methods of making and using the same
TW201806969A (zh) 嵌合抗原受體
JP2013518900A (ja) 炎症性ヒトTh17細胞の増殖および機能を決定的に調節するICOS
TWI862870B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
US20250195659A1 (en) T cell manufacturing compositions and methods
JP5840857B2 (ja) 細胞傷害性t細胞誘導用組成物
US20260115288A1 (en) T cell manufacturing compositions and methods
KR20210015873A (ko) 천연 킬러 세포를 제조하는 방법 및 이의 용도
JPWO2009145238A1 (ja) 免疫調節剤及びその利用
Messmer et al. Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status
HK40115457A (en) T cell manufacturing compositions and methods
CN109563481A (zh) 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
CN118574629A (zh) T细胞制备组合物和方法
HK40071072B (en) T cell manufacturing compositions and methods
HK40071072A (en) T cell manufacturing compositions and methods
HK40046063A (en) Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
HK40039283B (en) T cell manufacturing compositions and methods
HK40011995A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230302